Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea

Accuitis, Inc.40 enrolled

Overview

The study evaluated the safety, tolerability, and efficacy of ACCU-D1 when applied twice daily for 12 weeks in adult participants with moderate to severe acne rosacea. Two-third of the participants received ACCU-D1 while one-third of the participants received vehicle control.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Acne Rosacea

Interventions

ACCU-D1DRUG

ACCU-D1

VehicleDRUG

Placebo Comparator

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participant is male or non-pregnant and non-lactating female at least 18 years of age * Participant has a clinical diagnosis of stable papulopustular rosacea (type-2) * Participant has a total of ≥10 and ≤40 inflammatory lesions (papules, pustules, and nodules) on the face * Participant has ≤2 nodules on the face * Participant has an investigator's global assessment (IGA) score of ≥3 * If the participant is a woman of childbearing potential, she has a negative urine pregnancy test and agrees to use an approved effective method of birth control for the duration of the study * Participant is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair evaluation of rosacea or which exposes the participant to an unacceptable risk by study participation * Participant is willing and able to follow all study instructions and to attend all study visits * Participant is able to comprehend and willing to sign an informed consent form Exclusion Criteria: * Participant is pregnant, nursing, or planning to become pregnant during the duration of the study * Participant has used systemic glucocorticosteroids within 42 days prior to Visit 1 (inhaled and ocular glucocorticosteroids are permitted) * Participant has used systemic antibiotics within 28 days prior to Visit 1 * Participant has used any topical glucocorticosteroids on the face within 28 days prior to Visit 1 * Participant has used any prescription or over-the-counter product for the treatment of acne or rosacea within 14 days prior to Visit 1 * Participant is currently using any therapy that, in the investigator's opinion, is a photosensitizer (for example, phenothiazines, amiodarone, quinine, thiazides, sulphonamides, quinolones, etc.) * Participant currently has any skin disease (for example, psoriasis, atopic dermatitis, eczema), or condition (for example, actinic keratosis, photo-damage, sunburn, excessive hair, open wounds) that, in the investigator's opinion, might impair evaluation of rosacea or which exposes the subject to an unacceptable risk by study participation * Participant currently has, on the face, or has had on the face, any of the following within the specified period prior to Visit 1 that, in the investigator's opinion, might impair evaluation of rosacea or which exposes the subject to an unacceptable risk by study participation: * A cutaneous malignancy; 180 days * Experienced a sunburn; 14 days * Participant has facial hair, that in the investigator's opinion, might impair evaluation of rosacea or proper study medication application * Participant has a history of sensitivity to any of the ingredients in the study medications * Participant has participated in an investigational drug trial in which administration of an investigational study medication occurred within 30 days prior to Visit 1

Locations (2)

DS Research

Louisville, Kentucky, United States

DermResearch

Austin, Texas, United States

Outcomes

Primary Outcomes

Change From Baseline in Total Lesion Count at Week 12

Total lesion count was the sum of counts of the following lesion types (face only): Papule - raised inflammatory lesions, \<0.5 cm in diameter with no visible purulent material; Pustule - raised inflammatory lesions, \<0.5 cm in diameter with visible purulent material; Nodule - any circumscribed, inflammatory mass ≥0.5 cm in diameter.

Time frame: Baseline, Week 12

Secondary Outcomes

Percent Change From Baseline in Investigator's Global Assessment (IGA) Score at Weeks 2, 4, 8, and 12

The IGA score is an ordered categorical value ranging from 0 (clear) to 4 (severe). A lower score indicated improvement in the condition. Score 0 (clear): no papules or pustules, no nodules, none or barely perceptible erythema Score 1 (near clear): very few (≤3) papules and/or pustules, no nodules, very mild erythema Score 2 (mild): few papules and pustules present, no nodules, mild erythema Score 3 (moderate): several papules and pustules are the predominant features, ≤2 nodules may be present, moderate erythema Score 4 (severe): numerous papules and pustules, multiple nodules may be present, severe erythema

Time frame: Baseline; Weeks 2, 4, 8, and 12

Percentage of Participants Who Were Treatment Responders at Week 12

Treatment responders were defined as participants who have either (1) 2 ordinal or more reductions in the IGA score from baseline or (2) an IGA score of 0 or 1. The IGA score is an ordered categorical value ranging from 0 (clear) to 4 (severe). A lower score indicated improvement in the condition. Score 0 (clear): no papules or pustules, no nodules, none or barely perceptible erythema Score 1 (near clear): very few (≤3) papules and/or pustules, no nodules, very mild erythema Score 2 (mild): few papules and pustules present, no nodules, mild erythema Score 3 (moderate): several papules and pustules are the predominant features, ≤2 nodules may be present, moderate erythema Score 4 (severe): numerous papules and pustules, multiple nodules may be present, severe erythema

Time frame: Baseline, Week 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.